Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cells With Venetoclax as Consolidation Therapy in AML
NCT06152809Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2024
- Primary completion
- Nov 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML) (2 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Feb 2024; status: recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06152809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152809.